{"id":7877,"date":"2026-06-16T15:10:19","date_gmt":"2026-06-16T19:10:19","guid":{"rendered":"https:\/\/cqdm.org\/?post_type=project&#038;p=7877"},"modified":"2026-06-16T15:13:25","modified_gmt":"2026-06-16T19:13:25","slug":"development-of-oculomotor-based-digital-biomarkers-for-the-early-screening-and-monitoring-of-alzheimers-disease","status":"publish","type":"project","link":"https:\/\/cqdm.org\/en\/achievement\/funded-projects\/development-of-oculomotor-based-digital-biomarkers-for-the-early-screening-and-monitoring-of-alzheimers-disease\/","title":{"rendered":"Development of oculomotor-based digital biomarkers for the early screening and monitoring of Alzheimer\u2019s Disease"},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"is-style-suptitle wp-block-paragraph\"><strong>Principal Investigator<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Simon Ducharme<\/strong><br>McGill University<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"is-style-suptitle wp-block-paragraph\"><strong>Co-investigator<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"\"><b>\u00c9tienne deVillers-Sidani<br><\/b><\/span>McGill University<\/p>\n<\/div>\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span style=\"\">Project <\/span>of $ 1,140,606 over 2 years<\/h2>\n\n\n\n<ul class=\"wp-block-list is-style-checkmark\">\n<li><strong><strong>Supported by CQDM through:<\/strong><\/strong><br>Minist\u00e8re de l\u2019\u00c9conomie, de l\u2019Innovation et de l\u2019\u00c9nergie du Qu\u00e9bec (MEIE)<\/li>\n\n\n\n<li><strong><strong><strong>And by co-funding partner:<\/strong><\/strong><\/strong><br>&#8211; INNODEM Neurosciences<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Challenge:<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Early detection and monitoring of Alzheimer&#8217;s disease are significant challenges in clinical practice, research, and treatment response. The main obstacles are time constraints related to patient assessment and the lack of objective, cost-effective, disease-specific biomarkers.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Solution:<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Building on years of scientific literature demonstrating eye movement abnormalities in neurodegenerative disorders, Innodem Neurosciences has developed an eye-tracking technology that can accurately track eye movements, using only the camera of an iPad Pro. This technology has given rise to a set of mobile applications that easily capture and analyze eye movements, providing a non-invasive, rapid, and objective way to develop digital biomarkers of disease status and progression. A first set of digital biomarkers has recently been developed for multiple sclerosis, which has recently been approved for implementation in a mobile application (ETNA-MS\u2122). Using the same mobile eye-tracking technology, the research team&#8217;s main goal is to develop similar digital biomarkers for Alzheimer&#8217;s disease that can help with patient stratification, monitoring disease progression, and assessing response to treatment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Expected Achievements \/Impacts<\/strong>:<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The development of digital biomarkers has the potential to significantly improve and objectify clinical practice, reduce time and monetary costs for patients and the healthcare system, improve access to patients in remote areas, and provide a surrogate biomarker for the development of novel Alzheimer&#8217;s disease-modifying therapies. These advances would also allow Innodem to play a central role in advancing clinical assessment tools, providing the healthcare system with advances in personalized medicine.<\/p>\n","protected":false},"featured_media":3827,"template":"","project-category":[98],"class_list":["post-7877","project","type-project","status-publish","has-post-thumbnail","hentry","project-category-diagnostic-and-biomarkers"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project\/7877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/3827"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=7877"}],"wp:term":[{"taxonomy":"project-category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project-category?post=7877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}